Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
86
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy

Tian Wang1 The Eighth People’s Hospital of Shanghai, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4323-2878
ORCID Icon,
Feng Lin2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
,
Yujing Huang2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
,
Guowei Qian2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
,
Wenxi Yu2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
,
Haiyan Hu2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
,
Tong Ji3 Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China
,
Lina Tang2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-4763-9832
ORCID Icon &
Yang Yao2 Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, People’s Republic of China
 show all
Pages 2945-2952 | Received 19 Jun 2022, Accepted 13 Sep 2022, Published online: 27 Nov 2023

Figures & data

Table 1 Baseline Characteristics

Figure 1 Kaplan–Meier plot of progression-free survival (PFS). Blue line: PFS for patients in the GD group (gemcitabine/docetaxel). Red line: PFS for patients in the combination group (anlotinib and gemcitabine/docetaxel).

Figure 1 Kaplan–Meier plot of progression-free survival (PFS). Blue line: PFS for patients in the GD group (gemcitabine/docetaxel). Red line: PFS for patients in the combination group (anlotinib and gemcitabine/docetaxel).

Table 2 Treatment Response of the Two Groups

Figure 2 Best percentage change in target lesion size of patients. (The dashed lines represent the criteria for progressive disease (20% increase in target lesion size) and partial response (30% decrease in target lesion size) according to RECIST v1.1).

Figure 2 Best percentage change in target lesion size of patients. (The dashed lines represent the criteria for progressive disease (20% increase in target lesion size) and partial response (30% decrease in target lesion size) according to RECIST v1.1).

Table 3 The Most Common Adverse Events in the Two Groups

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.